Moderate To Severe Ulcerative Colitis clinical trials

Explore recruiting moderate to severe ulcerative colitis clinical trials.

Recruiting moderate to severe ulcerative colitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Ulcerative Colitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Prospective, Open-label Pilot Study to Evaluate Effector Mechanisms of Hyperbaric Oxygen Therapy in Patients with Moderate-to-Severe Ulcerative Colitis: The PARADOX study

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis

Slovakia, Spain, Slovenia, Belgium, France, Hungary +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

Austria, Denmark, Finland, Slovakia, Italy, Romania +11 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Orismilast for the treatment of moderate to severe ulcerative colitis

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe ulcerative colitis

Croatia, Romania, Greece, Italy, Belgium, Germany +6 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

Belgium, Hungary, Lithuania, Netherlands, Croatia, Czechia +10 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Moderate To Severe Ulcerative Colitis trials by city

Moderate To Severe Ulcerative Colitis in Toronto Moderate To Severe Ulcerative Colitis in Vancouver Moderate To Severe Ulcerative Colitis in Montreal Moderate To Severe Ulcerative Colitis in Calgary Moderate To Severe Ulcerative Colitis in Edmonton Moderate To Severe Ulcerative Colitis in Ottawa Moderate To Severe Ulcerative Colitis in Winnipeg Moderate To Severe Ulcerative Colitis in Quebec City Moderate To Severe Ulcerative Colitis in Hamilton Moderate To Severe Ulcerative Colitis in Kitchener Moderate To Severe Ulcerative Colitis in London Moderate To Severe Ulcerative Colitis in Halifax Moderate To Severe Ulcerative Colitis in New York Moderate To Severe Ulcerative Colitis in Los Angeles Moderate To Severe Ulcerative Colitis in Chicago Moderate To Severe Ulcerative Colitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease